- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Study finds intermittent fasting may protect against liver inflammation and cancer - Video
|
Overview
In a study published in the journal Cell Metabolism, researchers from the German Cancer Research Center (DKFZ) and the University of Tübingen showed that intermittent fasting on a 5:2 schedule can halt the development of liver inflammation and liver cancer caused by fatty liver disease.
The most prevalent chronic liver condition is non-alcoholic fatty liver disease (NAFLD), which can lead to serious complications such as liver inflammation (metabolic dysfunction-associated steatohepatitis, or NASH), liver cirrhosis, and even liver cancer if left untreated. Non-alcoholic fatty liver disease is primarily associated with obesity, which is on the rise globally. Consequently, affected countries are witnessing a sharp increase in cases of liver failure and liver cancer.
Intermittent fasting has been shown in several studies to effectively reduce weight and alleviate certain metabolic disorders. During fasting periods, the body undergoes autophagy, a cellular process that removes damaged components and promotes cellular repair. Intermittent fasting also improves insulin sensitivity, lowers inflammation, and enhances fat burning.
In the study, mice were fed a high-sugar and high-fat diet resembling the typical Western diet. One group had constant access to food, leading to weight gain and chronic liver inflammation. The other group practiced 5:2 intermittent fasting, where they ate normally for five days but fasted for two days each week. This intermittent fasting regimen aimed to assess its potential to protect the liver from fatty degeneration and chronic inflammation.
The results showed that despite consuming a high-calorie diet, the mice practicing intermittent fasting did not gain weight, showed fewer signs of liver disease, and had lower levels of biomarkers indicating liver damage. This resistance to fatty liver development was independent of total calorie intake, as the mice compensated for lost rations after fasting periods.
The findings revealed that the number and duration of fasting cycles, as well as the timing of the fasting phase, influenced protection against liver inflammation. A 5:2 dietary pattern and 24-hour fasting phases were more effective than other variants, especially with particularly unhealthy diets requiring more frequent fasting cycles.
Reference: Suchira Gallage, Mathias Heikenwalder, et al; A 5:2 intermittent fasting regimen ameliorates NASH and fibrosis and blunts HCC development via hepatic PPARα and PCK1; Cell Metabolism,2024; https://doi.org/10.1016/j.cmet.2024.04.015.
Speakers
Anshika Mishra is a dedicated scholar pursuing a Masters in Biotechnology, driven by a profound passion for exploring the intersection of science and healthcare. Having embarked on this academic journey with a passion to make meaningful contributions to the medical field, Anshika joined Medical Dialogues in 2023 to further delve into the realms of healthcare journalism.